Qiu et al., 2012 - Google Patents
A novel anti‐DR5 chimeric antibody and epirubicin synergistically suppress tumor growthQiu et al., 2012
View PDF- Document ID
- 14909785266645085692
- Author
- Qiu Y
- Zhang Z
- Shi J
- Liu S
- Liu Y
- Zheng D
- Publication year
- Publication venue
- IUBMB life
External Links
Snippet
Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis in a variety of tumor cells. TRAIL receptor 2 (DR5) expression is high in tumor cells, transformed cells, and clinical tumor specimens and is low in most normal cells and tissues; therefore …
- 229960001904 EPIRUBICIN 0 title abstract description 55
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pukac et al. | HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo | |
Spierings et al. | Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors | |
Tuthill et al. | TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells | |
Guo et al. | A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death | |
Yamamoto et al. | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma | |
Mizutani et al. | Doxorubicin sensitizes human bladder carcinoma cells to Fas‐mediated cytotoxicity | |
Straughn Jr et al. | Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model | |
Bellail et al. | DR5‐mediated DISC controls caspase‐8 cleavage and initiation of apoptosis in human glioblastomas | |
Kioi et al. | Interleukin‐13 receptor α2 chain: A potential biomarker and molecular target for ovarian cancer therapy | |
Köksal et al. | Treating osteosarcoma with CAR T cells | |
Jung et al. | The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine | |
Russo et al. | Exploring death receptor pathways as selective targets in cancer therapy | |
Park et al. | Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS-and JNK-mediated death receptor expression | |
Abdulghani et al. | Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis | |
Wang et al. | Multimeric anti-DR5 IgM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199 | |
Calzolari et al. | Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines | |
De Miguel et al. | TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells | |
Chao et al. | Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb | |
Wang et al. | Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer | |
Pettersson et al. | Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells | |
Qiu et al. | A novel anti‐DR5 chimeric antibody and epirubicin synergistically suppress tumor growth | |
Berkova et al. | CD74 interferes with the expression of fas receptor on the surface of lymphoma cells | |
Kulshrestha et al. | In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses | |
Smith et al. | Bortezomib sensitizes non–Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2 | |
Niwa et al. | Novel immunoliposome technology for enhancing the activity of the agonistic antibody against the tumor necrosis factor receptor superfamily |